Outlook Therapeutics (OTLK) Asset Utilization Ratio (2016 - 2025)

Outlook Therapeutics (OTLK) reported Asset Utilization Ratio of 0.38 for Q3 2025, down 7.44% quarter-over-quarter from 0.41 in Q2 2025.

Outlook Therapeutics (OTLK) Asset Utilization Ratio (2016 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 5 years of Asset Utilization Ratio data on file, last reported at 0.38 in Q3 2025.

Asset Utilization Ratio for Q3 2025 came in at 0.38, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 0.38 (changed N/A YoY), and the FY2025 annual result was 0.06, changed N/A from the prior year.
Asset Utilization Ratio retreated to 0.38 in Q3 2025 per OTLK's latest filing, from 0.41 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.41 in Q2 2025 and troughed at 0.38 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	0.55
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	0.60
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	1,422.00
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	0.47
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Outlook Therapeutics	51.56 Mn	43.81 Mn	-21,888.00	-

Download Data